Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of 4D Molecular Therapeutics Inc (NASDAQ: FDMT) was $9.21 for the day, down -20.05% from the previous closing price of $11.52. In other words, the price has decreased by -$20.05 from its previous closing price. On the day, 3.3 million shares were traded. FDMT stock price reached its highest trading level at $11.81 during the session, while it also had its lowest trading level at $9.05.
Ratios:
Our analysis of FDMT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.42 and its Current Ratio is at 8.42. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
On January 13, 2025, BMO Capital Markets Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $40 to $15.
On November 21, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $8.Morgan Stanley initiated its Underweight rating on November 21, 2024, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 16 ’25 when SCOTT BIZILY bought 1,635 shares for $10.95 per share.
Bizily Scott sold 1,635 shares of FDMT for $17,315 on Nov 17 ’25. The Chief Legal Officer now owns 3,594 shares after completing the transaction at $10.59 per share. On Nov 17 ’25, another insider, SCOTT BIZILY, who serves as the Officer of the company, bought 1,635 shares for $10.79 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 526214048 and an Enterprise Value of 243414048. For the stock, the TTM Price-to-Sale (P/S) ratio is 4385.14 while its Price-to-Book (P/B) ratio in mrq is 1.17. Its current Enterprise Value per Revenue stands at 2028.45 whereas that against EBITDA is -1.093.
Stock Price History:
The Beta on a monthly basis for FDMT is 2.94, which has changed by 0.99307954 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, FDMT has reached a high of $12.34, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is -13.72%, while the 200-Day Moving Average is calculated to be 47.25%.
Shares Statistics:
FDMT traded an average of 861.39K shares per day over the past three months and 772270 shares per day over the past ten days. A total of 57.14M shares are outstanding, with a floating share count of 52.02M. Insiders hold about 8.95% of the company’s shares, while institutions hold 65.83% stake in the company. Shares short for FDMT as of 1764288000 were 5049284 with a Short Ratio of 5.86, compared to 1761868800 on 4271739. Therefore, it implies a Short% of Shares Outstanding of 5049284 and a Short% of Float of 9.13.
Earnings Estimates
. The current rating of 4D Molecular Therapeutics Inc (FDMT) reflects the combined expertise of 10.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.82 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$2.14 and -$3.9 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$3.48, with 9.0 analysts recommending between -$2.6 and -$4.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $85M to a low estimate of $85k. As of. The current estimate, 4D Molecular Therapeutics Inc’s year-ago sales were $1kFor the next quarter, 7 analysts are estimating revenue of $5.34M. There is a high estimate of $8M for the next quarter, whereas the lowest estimate is $25k.
A total of 8 analysts have provided revenue estimates for FDMT’s current fiscal year. The highest revenue estimate was $85.12M, while the lowest revenue estimate was $204k, resulting in an average revenue estimate of $37.74M. In the same quarter a year ago, actual revenue was $37kBased on 6 analysts’ estimates, the company’s revenue will be $22.58M in the next fiscal year. The high estimate is $51.3M and the low estimate is $100k.
